Shalby Ltd. · NSE:SHALBY
Shalby — Q3 FY2021 Earnings Presentation
24 slides from Shalby's earnings presentation, Jan 15, 2021
Slide 1: Cover letter to stock exchanges
January 15, 2021 Shalby/SE/2020‐21/98 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://www.connect2nse.com/LISTING/ Through : http://listing.bseindia.com Sub:
Slide 2: Earnings Presentation Q3 FY2021
Earnings Presentation Q3 FY2021 SHALBY LIMITED (BSE CODE: 540797 I SHALBY, NSE CODE: SHALBY) A leader in Joint Replacement surgeries in India with an established chain of multi-specialty tertiary care hospitals.
Slide 3: Content
CONTENT 01 Q3 FY2021 PERFORMANCE HIGHLIGHTS 02 HOSPITAL BUSINESS UPDATE 03 VISIT OUR ESG PROFILE ON ESG WORLD 2
Slide 4: Q3 FY2021 Performance Highlights
Q3 FY2021 PERFORMANCE HIGHLIGHTS
Slide 5: Q3 FY2021 Performance Highlights
Q3 FY2021 PERFORMANCE HIGHLIGHTS Total Income up by 17.8% on q-o-q and 6.9% on y-o-y basis EBITDA up by 3.0% on q-o-q and 32.9% on y-o-y basis In Patient Count (Nos.) Surgeries Count 8,945 3,082 Total Income Operating EBITDA 7,573 in Q2 FY21 2,536 in Q2 FY21 Rs. 1,317 mn Rs. 323 mn Beds Occupied (No
Slide 6: Key Quarter Highlights
Q3 FY2021 PERFORMANCE HIGHLIGHTS Key Quarter Highlights Commenting on performance, Mr. Shanay Shah, President Said: “The company continues to respond to the pandemic and we are ▪ Treated over 2,700 Covid-19 patients in Q3 FY21 proud of the resiliency and perseverance demonstrated by the Shalby team
Slide 7: Total Income, EBITDA, PBT and PAT trends
Q3 FY2021 PERFORMANCE HIGHLIGHTS Total Income (Rs. Mn) EBITDA (Rs. Mn) and Margin 1,317 323 1,232 314 1,160 1,118 243 28.0% 24.5% 19.7% 129 408 11.1% (25) Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 PBT (Rs. Mn) and Margin PAT (Rs. Mn) and Margin 215 222 21.6% 139
Slide 8: Patient counts, ARPOB and surgery count
Q3 FY2021 PERFORMANCE HIGHLIGHTS In Patients Day Care Out Patients 5,701 9,838 4,945 5,026 5,050 80,501 8,711 8,945 74,333 68,130 7,573 3,763 56,619 3,664 32,305 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 ARPOB (Rs.) Surger
Slide 9: Revenue mix, occupancy and ALOS
Q3 FY2021 PERFORMANCE HIGHLIGHTS Revenue Mix by Care % of Revenue from Arthroplasty 43% 42% 13% 13% 16% 11% 10% 5% 4% 4% 3% 7% 82% 83% 85% 86% 17% 77% 13% 12% Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 In Patient Day Care Out Patient No of Bed Occupied Occupancy
Slide 10: Revenue by Hospital Specialty
Q3 FY2021 PERFORMANCE HIGHLIGHTS Revenue by Hospital Specialty 46% 44% 17% 13% 12% 9% 9% 10% 8% 7% 5% 4% 4% 4% 4% 3% Arthroplasty Critical Care & Orthopaedic Cardiac Science Nephrology Oncology Neurology Others General Medicine Q2 FY21 Q3 FY21 Number of Surgeries by Specialty Revenues by End Patient
Slide 11: Operating Expenses and Cost Mix
Q3 FY2021 PERFORMANCE HIGHLIGHTS Total Operating Expenses (Rs. Mn) Total Costs Mix (Rs. Mn) D&A Expenses 988 1,031 994 8% 8% 10% 8% 9% 17% 15% 9% 9% Other Expenses 805 15% 14% 15% 14% 16% 5% 2% 2% 2% 17% Employee Benefit 433 2% Expenses 63% 60% 63% 66% Purchase and Change in 50% Inventory Operative
Slide 12: Profit and Loss Statement
Q3 FY2021 PERFORMANCE HIGHLIGHTS Particulars (in Rs. Million) Q3 FY21 Q2 FY21 Q-o-Q Growth Q3 FY20 Y-o-Y Growth Revenue from Operations 1,293 1,093 18.3% 1,208 7.1% Other Income 24 25 (3.5)% 24 0.7% Total Income 1,317 1,118 17.8% 1,232 6.9% Expenses COGS 737 581 26.9% 734 0.4% % of Revenue 57% 53% 6
Slide 13: Operational Metrics
Q3 FY2021 PERFORMANCE HIGHLIGHTS Operational Metrics Q3 FY21 Q2 FY21 Q-o-Q Growth Q3 FY20 Y-o-Y Growth In Patient Count 8,945 7,573 18.1% 9,838 (9.1)% (Nos.) Day Care Patient Count 5,050 5,026 0.5% 5,701 (11.4)% (Nos.) Out Patient Count 68,130 56,619 20.3% 80,501 (15.4)% (Nos.) Surgeries Count 3,082
Slide 14: Hospital Business Update
SHALBY MULTI-SPECIALTY ——HOSPITALS— HOSPITAL BUSINESS UPDATE
Slide 15: Our Regional Presence
OUR REGIONAL PRESENCE Shalby has developed strong brand recognition in its core markets and is well positioned for further expansion ➢ National Presence ➢ International Presence (in Africa) PUNJAB ▪ Mohali – 145 beds RAJASTHAN ▪ Jaipur – 237 beds GUJARAT ▪ Ahmedabad o SG – 201 beds o Krishna – 220 b
Slide 16: Hospital Investment Journey
HOSPITAL INVESTMENT JOURNEY Return on Capital Employed currently reflects real estate investments and a relatively younger maturity portfolio Shalby Branding Phase Investment Phase 2 Hospitals with 228 beds Added 8 Hospitals with 1,734 new beds Q3 FY21 Occupancy of 45% reflects younger maturity Phas
Slide 17: Santa Cruz and Nashik Development Update
HOSPITAL BUSINESS UPDATE Santa Cruz Development Update Nashik Development Update Business Model: Revenue Sharing Business Model: Revenue Sharing Bed Capacity: 175 Bed Capacity: 113 Operating and Management Term: 30 + 30 years Operating and Management Term: 30 years Operationalization Year: FY 2024 O
Slide 18: SG Group, Vijay and Krishna hospitals
HOSPITAL BUSINESS UPDATE Commencement 2007 | 13 Years Catchment: Ahmedabad and surrounding areas of Gujarat, No. of beds / Occupancy 201 | 50.3% Rajasthan and Mumbai SG Type of Arrangement Leased – Fixed Rent • First hospital in Gujarat to use Imaged Intensified Television SG Group in Spine and Orth
Slide 19: Surat, Vapi, Indore and Jabalpur hospitals
HOSPITAL BUSINESS UPDATE Catchment: South Gujarat, North Maharashtra (including Commencement 2017 | 3 Years Mumbai) No. of beds / Occupancy 243 | 39.1% Surat • Treated More than 1500 Covid-19 patents Type of Arrangement Freehold • Empanelment of 2 major corporates: SBI & DGVCL Surat Group • Empanelm
Slide 20: Mohali, Jaipur and Zynova hospitals
HOSPITAL BUSINESS UPDATE Catchment: Punjab, Uttrakhand Commencement 2017 | 2+ Years • Collaboration done with elite orthopedics (Dr. Manuj Wadhwa) Mohali No. of beds / Occupancy 145 | 24.7% to enhance our Arthroplasty Business Type of Arrangement Freehold • Dr. Sawan Verma – DM – Neurology on board
Slide 21: Visit Our ESG Profile on ESG World
VISIT OUR ESG PROFILE ON ESG WORLD
Slide 22: ESG a Core Pillar of Strategy; Environment
Visit our ESG Profile on ESG a Core Pillar of Strategy Environment “The Company continues to focus on maintaining sustainability and “As part of environment strategy, the Company has adopted reducing environmental impact of its operations while exceeding various initiatives to restore environment, b
Slide 23: Social and Governance
Visit our ESG Profile on Social Governance “Our accountability goes beyond maintaining highest “We at Shalby believe in being transparent and we commit to standards of corporate behaviour towards our investors, adhere to good governance practices at all times, as it stakeholders and employees to cov
Slide 24: Disclaimer and Contact Details
DISCLAIMER and CONTACT DETAILS No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as